First Wave BioPharma Profit Margin

As of the most recent data (June 2026), FWBI shows a profit margin of -4961.87%. That compares with 15083.24% in the prior-year period — down 132.9% year over year. That is below the Healthcare sector average of 13.89%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, FWBI's profit margin is now -4961.87% (was 15083.24%) — a 132.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether First Wave BioPharma is outperforming or lagging.

The Healthcare sector average profit margin is about 13.89%. First Wave BioPharma is at -4961.87%, which is lower that average. That is roughly 35814.7% below the sector mean. Use the comparison chart on this page to see how FWBI stacks up against individual peers as well.

That compares with 15083.24% in the prior-year period — down 132.9% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare First Wave BioPharma with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has First Wave BioPharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -4961.87%) with ownership activity and broader fundamentals.